Short Interest Update on Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals (ALXN) : The short interest in Alexion Pharmaceuticals (ALXN) has increased from 5,729,082 to 6,028,749 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 1,598,176 shares are traded daily in the stock and only 4 days are left for the shorts to cover. The short open interest is 2.7% of the total shares in the hands of the public. The shorts in the stock have gone up by 299,667 shares, which is an increase of 5.2% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.

Alexion Pharmaceuticals (NASDAQ:ALXN): The stock opened at $137.07 on Wednesday but the bulls could not build on the opening and the stock topped out at $138.25 for the day. The stock traded down to $131.74 during the day, due to lack of any buying support eventually closed down at $132.12 with a loss of -3.86% for the day. The stock had closed at $137.42 on the previous day. The total traded volume was 1,395,620 shares.


In a related news, The Securities and Exchange Commission has divulged that Wagner Heidi L, officer (SVP, Global Government Affairs) of Alexion Pharmaceuticals Inc, had unloaded 222 shares at an average price of $137.14 in a transaction dated on August 8, 2016. The total value of the transaction was worth $30,445.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *